Interleukin‑17 promotes the development of cisplatin resistance in colorectal cancer

Sui,Guolong; Qiu,Yingna; Yu,Haijuan; Kong,Qingbin; Zhen,Baowen

doi:10.3892/ol.2018.9645

Interleukin‑17 promotes the development of cisplatin resistance in colorectal cancer

Authors:
- Guolong Sui
- Yingna Qiu
- Haijuan Yu
- Qingbin Kong
- Baowen Zhen
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Weihai Central Hospital, Weihai, Shandong 26440, P.R. China, Department of Anesthesia, Weihai Central Hospital, Weihai, Shandong 26440, P.R. China, Department of Nursing, Naiman County People's Hospital, Tongliao, Inner Mongolia 028300, P.R. China, Department of Surgery, Naiman County People's Hospital, Tongliao, Inner Mongolia 028300, P.R. China
Published online on: October 31, 2018 https://doi.org/10.3892/ol.2018.9645
Pages: 944-950
Copyright: © Sui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (DDP)‑based anticancer therapy is an important chemotherapeutic strategy for the treatment of colorectal cancer. However, its beneficial effect is largely compromised by adverse reactions, and more importantly, by the development of drug resistance. Therefore, it is crucial to determine the potential mechanism underlying the development of DDP resistance in colorectal cancer. Interleukin‑17 (IL‑17) is a proinflammatory cytokine that has been found to serve an important role in the host defense during cancer development. It has been suggested that IL‑17 is key to promoting the development of resistance to DDP in several major types of cancer. However, the role of IL‑17 in DDP resistance in colorectal cancer has not been extensively investigated. In the present study, it was observed that IL‑17 was significantly upregulated in colorectal tumor samples, compared with the adjacent tissues. Furthermore, IL‑17 was found to promote the viability of HCT116 colorectal cells treated with DDP, whilst blocking IL‑17 signaling leading to HCT116 cell apoptosis. IL‑17 was also shown to regulate the expression of several apoptosis‑related proteins, including phosphorylated‑protein kinase B (p‑Akt), apoptosis regulator BAX (Bax), apoptosis regulator Bcl‑2 (Bcl‑2) and serine/threonine‑protein kinase mTOR (mTOR). These findings indicated that IL‑17 facilitates the development of DDP resistance in colorectal cancer by inhibiting cancer cell apoptosis through targeting p‑Akt, Bax, Bcl‑2 and mTOR. Overall, the findings of the present study suggest that a combination of DDP and an IL‑17 inhibitor may prove to be a highly efficient strategy for colorectal cancer treatment.

View Figures

View References

1	McQuade RM, Stojanovska V, Bornstein JC and Nurgali K: Colorectal cancer chemotherapy: The evolution of treatment and new approaches. Curr Med Chem. 24:1537–1557. 2017. View Article : Google Scholar : PubMed/NCBI
2	Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dise. 5:e12572014. View Article : Google Scholar
3	Valsecchi ME: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med. 373:12702015. View Article : Google Scholar
4	Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
5	Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014:1491852014. View Article : Google Scholar : PubMed/NCBI
6	Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T and Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
7	Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F and Miossec P: Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 12:1092–1099. 2000. View Article : Google Scholar : PubMed/NCBI
8	Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, et al: Interleukin-17A Promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol. 12:1268–1279. 2017. View Article : Google Scholar : PubMed/NCBI
9	Carvalho DFG, Zanetti BR, Miranda L, Hassumi-Fukasawa MK, Miranda-Camargo F, Crispim JCO and Soares EG: High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol Lett. 13:1925–1931. 2017. View Article : Google Scholar : PubMed/NCBI
10	Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G and Zou W: Th17 cells in cancer: Help or hindrance? Carcinogenesis. 32:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hu J, Ye H, Zhang D, Liu W, Li M, Mao Y and Lu Y: U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues. Oncol Lett. 6:993–999. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ernst M and Putoczki T: IL-17 cuts to the chase in colon cancer. Immunity. 41:880–882. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, et al: Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity. 41:1052–1063. 2014. View Article : Google Scholar : PubMed/NCBI
14	Chang Y, Al-Alwan L, Risse PA, Halayko AJ, Martin JG, Baglole CJ, Eidelman DH and Hamid Q: Th17-associated cytokines promote human airway smooth muscle cell proliferation. FASEB J. 26:5152–5160. 2012. View Article : Google Scholar : PubMed/NCBI
15	Yang B, Kang H, Fung A, Zhao H, Wang T and Ma D: The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014:6237592014. View Article : Google Scholar : PubMed/NCBI
16	Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, et al: IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 3:34562013. View Article : Google Scholar : PubMed/NCBI
17	Boulikas T and Vougiouka M: Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep. 10:1663–1682. 2003.
18	Zhang HB, Lu P, Guo QY, Zhang ZH and Meng XY: Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway. Oncol Lett. 5:722–728. 2013. View Article : Google Scholar : PubMed/NCBI
19	Al-Fatlawi AA, Al-Fatlawi AA, Irshad M, Zafaryab M, Rizvi MM and Ahmad A: Rice bran phytic acid induced apoptosis through regulation of Bcl-2/Bax and p53 genes in HepG2 human hepatocellular carcinoma cells. Asian Pac J Cancer Prev. 15:3731–3736. 2014. View Article : Google Scholar : PubMed/NCBI
20	Ji Y and Zhang W: Th17 cells: Positive or negative role in tumor? Cancer Immunol Immunother. 59:979–987. 2010. View Article : Google Scholar : PubMed/NCBI
21	Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T and Raoul W: A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer. 17:2202017. View Article : Google Scholar : PubMed/NCBI
22	Al-Samadi A, Moossavi S, Salem A, Sotoudeh M, Tuovinen SM, Konttinen YT, Salo T and Bishehsari F: Distinctive expression pattern of interleukin-17 cytokine family members in colorectal cancer. Tumor Bio. 37:1609–1615. 2016. View Article : Google Scholar